The Schizophrenia Drug Landscape Infographic
Download the Infographic to Explore:
- A Pipeline Centred in Early Development: 59% of schizophrenia assets have reached clinical trials, with development predominantly in early to mid-stage trials.
- The Shift Beyond Dopamine-Driven Therapies: The approval of Kar-XT – the first non-dopaminergic antipsychotic – marks a pivotal shift in mechanism validation.
- Emerging Mechanisms and Novel Approaches: From muscarinic receptor targeting to synaptic regeneration strategies, new mechanisms of action are advancing beyond traditional pathways.
- Key Upcoming Milestones and Trial Readouts: Discover the late-stage programmes, regulatory developments, and notable pipeline risks shaping the near-term schizophrenia landscape.
You May Also Be Interested In…
Learn More About Psychiatric
What is Beacon Psychiatric?
- The Most Comprehensive Way to Search the Psychiatric Drug Development Landscape: Unique search ontologies based on Psychiatric drug and trial characteristics
- Market Leading Approach to Psychiatric Preclinical & Clinical Data Curation: Manual curation of key Psychiatric research and development data points by Psychiatric research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Psychiatric company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
